Relmada Therapeutics, Inc. (RLMD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
2222 Ponce de Leon Boulevard
Coral Gables, FL 33134
United States of America (the)
Phone
786 629 1376
Website
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
June 20, 2014
| Name | Title | Pay | Year Born |
| Sergio Traversa | Chief Executive Officer & Director | 3.94M | 1960 |
| Paul E. Kelly | Chief Operating Officer & Director | 1.96M | 1957 |
| Charles S. Ence | Chief Accounting & Compliance Officer | 2.17M | 1965 |
| Maged S. Shenouda | Chief Financial Officer | 2.64M | 1964 |
| Richard Mangano | Consultant | 0 | 1950 |
| Raj S. Pruthi | Chief Medical Officer of Urology | 0 | 1967 |
| Andrew Cutler | Senior Clinical Development Advisor | 0 | N/A |
| Gina DiGuglielmo | Vice President & Head of Clinical Operations | 0 | N/A |
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology firm, concentrating its efforts on developing various therapeutic solutions for ailments affecting the central nervous system (CNS) and other disorders. The company's primary drug candidate is Esmethadone (also known as d-methadone, dextromethadone, or REL-1017), a novel chemical compound. This N-methyl-D-aspartate receptor antagonist is currently undergoing Phase 3 clinical trials, investigating its efficacy as both a supplementary and standalone treatment for major depressive disorder in adult patients. Founded in 2004, the enterprise maintains its corporate headquarters in Coral Gables, Florida.